Searching over 5,500,000 cases.

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

PDL Biopharma, Inc. v. Sun Pharmaceutical Industries

July 31, 2009


The opinion of the court was delivered by: Katharine S. Hayden, U.S.D.J.


Before the Court is Sun Pharmaceutical Industries Ltd.'s ("Sun") motion for reconsideration of the Court's March 31, 2009 opinion finding infringement by Sun's ANDA product. The Court assumes familiarity with the relevant background and procedural facts in that decision. (D.E. 190.)

I. Sun's Reconsideration Motion

On this motion, Sun primarily argues that the Court improperly found infringement based on a comparison of the accused ANDA product with Cardene I.V. (the commercial embodiment of EKR's "405 patent), rather than based upon a comparison of the accused product with the claims of the "405 patent. Sun also argues that the Court erroneously "adopted a theory of literal infringement." (Sun Recons. Mot. 6.) Sun submits that the "405 patent requires that Sun's product simultaneously (1) be isotonic; and (2) have at least 1.0 mg/ml nicardipine hydrochloride. Sun contends that its ANDA product cannot literally infringe because it is not isotonic in the ampul and it is below 1.0 mg/ml at the point of administration. (Sun Recons. Mot. 8.)

Sun argues that the Court adopted a construction of the "405 patent claims that EKR's predecessor expressly disclaimed before the U.S. Patent and Trademark Office in its efforts to obtain the "405 patent. Sun claims that this error arises from the Court's "misunderstanding that literal infringement" was still at issue with respect to the concentration of nicardipine being "at least 1 mg/ml." Sun claims that EKR's counsel stated it was abandoning its literal infringement argument in an email to which the Court was not privy, as was excerpted in its briefing. (Sun Recons. Mot. 2.)

Sun submits that the Court's ruling erred in that it "adopt[ed] a claim construction that eliminated the "at least 1 mg/ml' limitation of the "405 patent's claims-a limitation that EKR adopted specifically to ameliorate concerns expressed by the PTO in the prosecution history." (Sun Recons. Mot. 8.) Sun points to the patent prosecution history before the PTO because the examiner had rejected a claim for a "therapeutically effective amount of nicardipine" and did not specify a concentration. The examiner rejected that claim because prior art showed nicardipine at 0.6 mg/ml. Sun claims that because EKR earlier narrowed its claim to get a patent means that EKR cannot now recapture the excluded subject matter. The Court rejected this argument in its March 31 opinion, stating "because, with respect to the nicardipine concentration specification, Sun"s ANDA product literally infringes in the ampul with a concentration of 2.5 mg/ml." (D.E. 190, p. 28).

II. Law Governing Reconsideration Motions

Local Civil Rule 7.1(i), which governs motions for reconsideration, provides:

A motion for reconsideration shall be served and filed within 10 business days after the entry of the order or judgment on the original motion by the Judge or Magistrate Judge. A brief setting forth concisely the matter or controlling decisions which the party believes the Judge or Magistrate Judge has overlooked shall be filed with the Notice of Motion.

D.N.J. Local Civil Rule 7.1(i). A motion under Rule 7.1(i) may be granted if: "(1) [A]n intervening change in the controlling law has occurred, (2) evidence not previously available has become available, or (3) it is necessary to correct a clear error of law or prevent manifest injustice." North River Ins. Co. v. CIGNA Reinsurance Co., 52 F.3d 1194, 1218 (3d Cir. 1995). "Relief by way of a motion for reargument is an extraordinary remedy that is to be granted very sparingly." Capell v. Lowe's Home Imp. of Toms River, 2005 WL 2373415, *2 (D.N.J. Sept. 27, 2005) (J. Thompson). "The local rule governing reconsideration does not contemplate a recapitulation of arguments considered by the court before rendering its decision." Id. The rule generally permits reconsideration only where dispositive factual matters or controlling decisions of law were presented to the court but were overlooked. Id. (internal citations omitted); Khair v. Campbell Soup Co., 893 F. Supp. 316, 337 (D.N.J. 1995).

III. Discussion

A. Comparison of Sun's ANDA product to the '405 Patent's Claims

Sun's argument that the Court based its finding of infringement upon a comparison of Sun's ANDA product to Cardene I.V. rather than the "405 claims ignores the Court's focus on the "405 claims in its March 31, 2009 opinion and the findings made that each claim was met by Sun's ANDA product. First, on pages 6 and 7 of the March 31 opinion the Court recited the proper legal standard in observing that the patent claims alone vest the patent holder's right to exclude and that a finding of infringement requires that the accused product contains every limitation as outlined in the patent claims. (D.E. 190.) And the Court properly focused on whether Sun's ANDA product met every limitation in the "405 claims.

On page 12, the Court set out how Sun's ANDA would use a buffer solution and sorbitol to stabilize its ANDA product just as is done under the "405 patent. On page 20, in addressing the specifics of Sun's infringement, the Court states that Sun's ANDA would infringe the "405 patent's claim 1 because the ANDA product has a nicardipine concentration of at least 1 mg/ml and an adequate non-chloride compound to render it isotonic. Likewise, on page 28, the Court found that Sun's product in the ampul is "literally"within the "405 patent's limitation in claims 1 and 3 of a concentration of "at least' 1.0 mg/ml of nicardipine hydrochloride. Starting on page 24, under the doctrine of equivalents, the Court assessed the function, way, and result of the sorbitol in the "405 patent and the function, way, and result of the non-chloride compound in Sun's ANDA product. The Court found that both components, as parts of their respective compositions, served the same function, acted in the same way, and reached the same result (i.e. the ANDA product and the "405 patent). On page 31, the Court concluded that-under the doctrine of ...

Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.